Genotropin (PN-180,307) Somatropin + Control-no treatment
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infant, Small for Gestational Age
Conditions
Infant, Small for Gestational Age
Trial Timeline
Feb 1, 2008 → Dec 1, 2013
NCT ID
NCT00627523About Genotropin (PN-180,307) Somatropin + Control-no treatment
Genotropin (PN-180,307) Somatropin + Control-no treatment is a phase 3 stage product being developed by Pfizer for Infant, Small for Gestational Age. The current trial status is completed. This product is registered under clinical trial identifier NCT00627523. Target conditions include Infant, Small for Gestational Age.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00627523 | Phase 3 | Completed |
Competing Products
20 competing products in Infant, Small for Gestational Age
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| somatropin | Eli Lilly | Phase 3 | 77 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| epoetin beta + epoetin beta | Roche | Pre-clinical | 23 |
| Prevenar (13v) | Pfizer | Pre-clinical | 22 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV | Sanofi | Phase 3 | 76 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Radiprodil | UCB | Phase 2 | 49 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |